Full Papers
Real-world safety and effectiveness of canakinumab in patients with cryopyrin-associated periodic fever syndrome: a long-term observational study in Japan
K. Hosono1, C. Kato2, T. Sasajima3
- Medical division, Novartis Pharma K.K, Japan. kumiko.hosono@novartis.com
- Re-examination, Patient Safety, Novartis Pharma K.K, Japan.
- Analytics Japan, Novartis Pharma K.K, Japan.
CER13555
2022 Vol.40, N°8
PI 1543, PF 1553
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 36106540 [PubMed]
Received: 12/05/2020
Accepted : 24/06/2022
In Press: 14/09/2022
Published: 14/09/2022
Abstract
OBJECTIVES:
A post-marketing all-patient surveillance program was conducted to evaluate the safety and effectiveness of canakinumab, a monoclonal anti-interleukin-1β antibody, in patients in Japan with cryopyrin-associated periodic fever syndrome (CAPS), including familial cold auto-inflammatory syndrome, Muckle-Wells syndrome, and neonatal onset multisystem inflammatory disease.
METHODS:
All patients with CAPS who received canakinumab treatment after drug approval in Japan were registered in this non-interventional, observational study. The observation period per patient was two years. Patients newly treated with canakinumab (New patients; NP) and those continuously treated with canakinumab following clinical trials (Roll-over patients; RP) were included. Data collection of clinical symptoms affecting physical function and prognosis was not mandated but assessed where available. Here, the interim results are reported.
RESULTS:
Of 87 patients in the safety set, the proportion of patients with any adverse drug reactions (ADRs) and any serious ADRs was 31.03% and 3.45%, respectively. The most common ADRs reported under system organ class were infections and infestations (20.69%). Of 84 patients in the effectiveness set, 75.76% and 83.33% of NP and RP, respectively, were responders at Week 24, achieving complete response without relapse. Responder rates were maintained up to Week 104. Clinical symptoms affecting physical function and prognosis remained unchanged in over half of those patients.
CONCLUSIONS:
Interim results provided the safety profile of canakinumab in a real-world setting, and identified no new safety concerns. Treatment with canakinumab has suggested sustained remission in the majority of patients in the real-world setting.
